...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR 2018

"....Management has had very little success in unlocking value from either of these companies...."

We have to wait until Zenith is far enough along with their studies so that a pharma has enough data to do a deal or a buyout.  We're just not there yet.

"....Management at Zenith says it is worth somewhere around $3 US/share the best they have done in financing is $1/share...."

You're comparing now (Enterprise Value) vs 2016 (financing). When they did the last financing at $1 /share, the Enterprise Value estimate was only $1 /share.

Share
New Message
Please login to post a reply